Silence Therapeutics (SLN) - Long-Term Debt to Capital

Silence Therapeutics (SLN) specializes in developing innovative drugs for heart and blood therapies. This price chart illustrates the asset's dynamics, where the indicator stands at 0.00. The business delegates drug manufacturing and testing to external contractors to optimize logistics. The strategy relies on RNA interference, while collaborations with market leaders reduce financial losses. Portfolio validation through global licenses minimizes technological risks.

This indicator assesses financial stability by comparing liabilities with a maturity of over one year against equity to identify hidden leverage risks. By analyzing the ratio of long-term loans to equity, an investor can determine the degree of Silence Therapeutics (SLN) dependence on external financing, which is critical for a biotech firm whose revenues are limited to licensing payments in the absence of direct pricing power.